Join
Live feed
·
NEWSReleasevia Quantisnow
Baudax Bio Inc. logo

Baudax Bio Announces Corporate Update; Co. Says Phase 1/2a Clinical Study Of TI-168 In Hemophilia A with FVIII Inhibitors Projected To Begin In Q1 2024

ByQuantisnow·Wall Street's wire, on your screen.
BXRX· Baudax Bio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BXRX (Baudax Bio Inc.) and more on Quantisnow.

Baudax Bio Announces Corporate Update; Co. Says Phase 1/2a Clinical Study Of TI-168 In Hemophilia A with FVIII Inhibitors Projected To Begin In Q1 2024 | Quantisnow